TokenPost·
Halozyme Shares Fall More Than 13% After Leerink Downgrade
Third-quarter revenue rose 39% to $493 million, while non-GAAP earnings came in 3 cents above estimates.
More news
- TokenPostHain Celestial Q1 Revenue Seen Falling 23% Ahead of Nov. 9 Results
- TokenPostHeron Therapeutics Sets Nov. 9 Call to Report Third-Quarter Results
- TokenPostKaspi.kz Q3 Preview Highlights $2.99 EPS and $2.71 Billion Revenue Estimates
- TokenPostMeta Adds Custom Spaces to Its Muse AI Assistant for Interactive Tasks
- TokenPostStablecoin Issuance and Redemptions Change Circulating Supply
- TokenPostCECO Environmental Sets Q3 Results for Nov. 9 After Thermon Deal